Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Gene Amplification”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Large-scale testing (Phase 3)Study completedNCT02573324
What this trial is testing

ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Who this might be right for
GlioblastomaGliosarcoma
AbbVie 691
Large-scale testing (Phase 3)Not Yet RecruitingNCT07109531
What this trial is testing

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 286
Testing effectiveness (Phase 2)Ended earlyNCT04515394
What this trial is testing

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Who this might be right for
Colorectal Neoplasms
EMD Serono Research & Development Institute, Inc. 3
Testing effectiveness (Phase 2)Ended earlyNCT00479856
What this trial is testing

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Who this might be right for
Relapsed Breast CancerNeoplasms, Breast
GlaxoSmithKline 9
Large-scale testing (Phase 3)UnknownNCT06110663
What this trial is testing

HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 314
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Large-scale testing (Phase 3)Looking for participantsNCT06829459
What this trial is testing

Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Who this might be right for
Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 350
Early research (Phase 1)Not Yet RecruitingNCT04933422
What this trial is testing

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

Who this might be right for
Glioblastoma
Crimson Biopharm Inc. 72
Testing effectiveness (Phase 2)UnknownNCT04880811
What this trial is testing

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 43
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Not applicableUnknownNCT06022276
What this trial is testing

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Who this might be right for
Solid TumorEGFR Amplification
Tianjin Medical University Second Hospital 46
Testing effectiveness (Phase 2)Study completedNCT01520870
What this trial is testing

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Who this might be right for
GlioblastomaBrain Tumor, Recurrent
Grupo Español de Investigación en Neurooncología 49
Early research (Phase 1)Active Not RecruitingNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 93
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06452433
What this trial is testing

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 91
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Load More Results